Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Udenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 0.80 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | PDE9A | O76083 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE6C | P51160 | 1/20 | 0.49 |
| ▸ | PDE1A | P54750 | 1/20 | 0.49 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Udenafil SCHEMBL438563 | 1.00 | PDE5A (0.80) | PDE5APDE2APDE9APDE4APDE6C | |
| SCHEMBL325269 | 0.96 | PDE5A (0.74) | PDE5APDE2APDE9APDE4APDE6C | |
| SCHEMBL3235482 | 0.89 | PDE5A (0.65) | PDE5A | |
| Udenafil SCHEMBL120993 | 0.89 | PDE5A (1.00) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL30452348 | 0.89 | PDE5A (1.00) | PDE5APDE2APDE9APDE4APDE6C | |
| SCHEMBL18416780 | 0.88 | PDE5A (0.69) | PDE5A | |
| SCHEMBL18269491 | 0.88 | PDE5A (0.62) | PDE5A | |
| Udenafil SCHEMBL8054822 | 0.86 | PDE5A (0.94) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8055433 | 0.86 | PDE5A (0.94) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8055636 | 0.86 | PDE5A (0.94) | PDE5APDE2APDE9APDE4APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4579 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107071-A1 | COMBINATION THERAPY | Retension Pharmaceuticals, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| US-12576081-B2 | Methods and compositions for improving exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in single ventricular heart disease, using udenafil compositions | MEZZION PHARMA CO., LTD. (KR) | 2026-03-17 | — | — | US | claimed |
| EP-4687904-A1 | PDE5 INHIBITOR FOR USE IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH MITOCHONDRIAL COMPLEX IV DEFICIENCY | Charité - Universitätsmedizin Berlin (DE) | 2026-02-11 | — | — | EP | claimed |
| US-20260021100-A1 | METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATION | ARIBIO CO LTD (KR) | 2026-01-22 | — | — | US | claimed |
| EP-4656194-A1 | COMPOSITION FOR PREVENTING OR TREATING POST-TRAUMATIC STRESS DISORDER, COMPRISING PHOSPHODIESTERASE TYPE 5 INHIBITOR AS ACTIVE INGREDIENT | Aribio Co., Ltd (KR) | 2025-12-03 | — | — | EP | claimed |
| WO-2025134070-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | ARIBIO CO., LTD. (KR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025134069-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | ARIBIO CO., LTD. (KR) | 2025-06-26 | — | — | WO | claimed |
| US-20250205239-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | ARIBIO CO LTD (KR) | 2025-06-26 | — | — | US | claimed |
| US-20250195531-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2025-06-19 | — | — | US | claimed |
| EP-4568692-A1 | TYROSINE KINASE INHIBITOR AND ACTIVIN TYPE 2 RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATING PULMONARY ARTERIAL HYPERTENSION (PAH) | GB002, Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| EP-1898879-A1 | RAPIDLY ABSORBING ORAL FORMULATIONS OF PDE5 INHIBITORS | SCHERING CORPORATION (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2008028914-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2008-03-13 | — | — | WO | claimed |
| WO-2008026156-A2 | THERAPEUTIC COMPOSITIONS COMPRISING A SPECIFIC ENDOTHELIN RECEPTOR ANTAGONIST AND A PDE5 INHIBITOR | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-06 | — | — | WO | claimed |
| EP-1874309-A1 | ROFLUMILAST FOR THE TREATMENT OF PULMONARY HYPERTENSION | Nycomed GmbH (DE) | 2008-01-09 | — | — | EP | claimed |
| WO-2007113243-A2 | USE OF PDE 5 INHIBITORS FOR THE TREATMENT OF OVERACTIVE BLADDER | INVESTIGACIÓN Y CLÍNICA ANDROLÓGICAS S.L. (ES) | 2007-10-11 | — | — | WO | claimed |
| WO-2007067570-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2007-06-14 | — | — | WO | claimed |
| WO-2007039075-A2 | PDE INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF UROLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-04-12 | — | — | WO | claimed |
| US-20070031349-A1 | Rapidly absorbing oral formulations of PDE 5 inhibitors | SCHERING CORPORATION | 2007-02-08 | — | — | US | claimed |
| WO-2007002125-A1 | RAPIDLY ABSORBING ORAL FORMULATIONS OF PDE5 INHIBITORS | SCHERING CORPORATION (US) | 2007-01-04 | — | — | WO | claimed |
| WO-2006111495-A1 | ROFLUMILAST FOR THE TREATMENT OF PULMONARY HYPERTENSION | NYCOMED GMBH (DE) | 2006-10-26 | — | — | WO | claimed |